These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 2387490)
1. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection]. Robles-Diáz G; Aceves G; Galván E Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490 [TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer]. Chen SB Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873 [TBL] [Abstract][Full Text] [Related]
3. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer]. Huang C; Bei L; Liu T Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693 [TBL] [Abstract][Full Text] [Related]
4. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer. Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798 [TBL] [Abstract][Full Text] [Related]
6. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Robles-Díaz G; Díaz-Sánchez V; Fernández-del Castillo C; Morales M; Aceves G; Galván E; Altamirano A Am J Gastroenterol; 1991 May; 86(5):591-4. PubMed ID: 2028950 [TBL] [Abstract][Full Text] [Related]
7. Gallbladder bile tumor marker quantification for detection of pancreato-biliary malignancies. Brockmann J; Emparan C; Hernandez CA; Sulkowski U; Dietl KH; Menzel J; Wolters H; Glodny B; Senninger N Anticancer Res; 2000; 20(6D):4941-7. PubMed ID: 11326643 [TBL] [Abstract][Full Text] [Related]
8. [SC6 antigen for the diagnosis of pancreatic cancer before operation]. Guo XZ; Liu ZF; Ai R Zhonghua Yi Xue Za Zhi; 1993 Jan; 73(1):26-8, 61-2. PubMed ID: 8389232 [TBL] [Abstract][Full Text] [Related]
9. Intraoperative fine needle aspiration of pancreatic and extrahepatic biliary masses. Earnhardt RC; McQuone SJ; Minasi JS; Feldman PS; Jones RS; Hanks JB Surg Gynecol Obstet; 1993 Aug; 177(2):147-52. PubMed ID: 8342094 [TBL] [Abstract][Full Text] [Related]
10. Low efficacy of serum levels of CA 19-9 in prediction of malignant diseases in asymptomatic population in Taiwan. Chang CY; Huang SP; Chiu HM; Lee YC; Chen MF; Lin JT Hepatogastroenterology; 2006; 53(67):1-4. PubMed ID: 16506366 [TBL] [Abstract][Full Text] [Related]
11. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?]. Mery CM; Duarte-Rojo A; Paz-Pineda F; Gómez E; Robles-Díaz G Rev Invest Clin; 2001; 53(6):511-7. PubMed ID: 11921523 [TBL] [Abstract][Full Text] [Related]
12. [Role of carcinoembryonic antigen, carbohydrate antigen 19-9 and cytology of bile in diagnosis of biliary and pancreatic cancer]. Matsuda M; Shimizu Y; Chikamatsu E; Takayanagi K; Ishigure H; Murakami S; Odani K Nihon Geka Gakkai Zasshi; 1991 Jun; 92(6):716-21. PubMed ID: 1886576 [TBL] [Abstract][Full Text] [Related]
13. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919 [TBL] [Abstract][Full Text] [Related]
14. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Ozkan H; Kaya M; Cengiz A Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813 [TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of serum TAC-41 in various digestive cancers]. Sato S; Yamanaka T; Kimura K Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083 [TBL] [Abstract][Full Text] [Related]
16. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer]. Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018 [TBL] [Abstract][Full Text] [Related]
17. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048 [TBL] [Abstract][Full Text] [Related]
18. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma. Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154 [TBL] [Abstract][Full Text] [Related]
19. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259 [TBL] [Abstract][Full Text] [Related]
20. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies. Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]